Recent Security Class Actions

Cerevel Therapeutics Holdings Inc. Common Stock (NASDAQ: CERE)

40 Days left to seek lead plaintiff status.

Company Name:Cerevel Therapeutics Holdings Inc. Common Stock
Stock Symbol:NASDAQ: CERE
Class Period Start:10/11/2023
Class Period End (inclusive):08/01/2024
Filing Deadline:06/02/2025

According to the Complaint, Cerevel Therapeutics Holdings, Inc. was a biopharmaceutical company co-founded in 2018 by contributions of neuroscience assets from Pfizer Inc. and monetary investment from Bain Capital Investors, Inc. In 2020, Cerevel went public through a merger with a Special Purpose Acquisition Company, Arya Sciences Acquisition Corp. II. This lawsuit was filed against Cerevel and its two controlling shareholders. The lawsuit seeks to recover damages on behalf of shareholders damaged by alleged omissions and wrongdoing in connection with Cerevel’s October 16, 2023 secondary stock offering and related statements in Cerevel’s January 18, 2024 Proxy Statement for AbbVie’s acquisition of Cerevel.

 

Cerevel Therapeutics Holdings Inc. Common Stock (NASDAQ: CERE) Claim Form

Name(Required)
Address
This field is for validation purposes and should be left unchanged.